Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36697107)

  • 1. Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer.
    Xu M; Tsunedomi R; Kiyotani K; Tomochika S; Furuya K; Nakajima M; Matsui H; Tokumitsu Y; Shindo Y; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Hazama S; Nagano H
    Anticancer Res; 2023 Feb; 43(2):613-620. PubMed ID: 36697107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
    Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
    Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
    Front Immunol; 2018; 9():3185. PubMed ID: 30733724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative capacity of senescent lymphocytes. II. Monoclonal antibody stimulation of mucosal and systemic lymphocytes via T cell activation molecules, CD3 epsilon, T cell receptor V beta 8 chain, and phosphatidylinositol-linked anchored receptors THY-1 and LY-6A.2/TAP.
    Green-Johnson JM; Szewczuk MR
    Reg Immunol; 1990-1991; 3(6):323-35. PubMed ID: 1983438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases.
    Høye E; Dagenborg VJ; Torgunrud A; Lund-Andersen C; Fretland ÅA; Lorenz S; Edwin B; Hovig E; Fromm B; Inderberg EM; Greiff V; Ree AH; Flatmark K
    Gigascience; 2022 Dec; 12():. PubMed ID: 37161965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two subsets of human T lymphocytes expressing gamma/delta antigen receptor are identifiable by monoclonal antibodies directed to two distinct molecular forms of the receptor.
    Bottino C; Tambussi G; Ferrini S; Ciccone E; Varese P; Mingari MC; Moretta L; Moretta A
    J Exp Med; 1988 Aug; 168(2):491-505. PubMed ID: 2970517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s).
    Ciccone E; Ferrini S; Bottino C; Viale O; Prigione I; Pantaleo G; Tambussi G; Moretta A; Moretta L
    J Exp Med; 1988 Jul; 168(1):1-11. PubMed ID: 2456364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies which react with the T cell receptor gamma/delta recognize different subsets of CD3+WT31- T lymphocytes.
    Ferrini S; Prigione I; Bottino C; Ciccone E; Tambussi G; Mammoliti S; Moretta L; Moretta A
    Eur J Immunol; 1989 Jan; 19(1):57-61. PubMed ID: 2784109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.
    Li D; Fu Q; Li M; Li J; Yin C; Zhao J; Li F
    Future Oncol; 2017 May; 13(12):1115-1127. PubMed ID: 28110551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal High-Throughput Sequencing of the T-Cell Receptor Repertoire Reveals Dynamic Change and Prognostic Significance of Peripheral Blood TCR Diversity in Metastatic Colorectal Cancer During Chemotherapy.
    Chen YT; Hsu HC; Lee YS; Liu H; Tan BC; Chin CY; Chang IY; Yang CY
    Front Immunol; 2021; 12():743448. PubMed ID: 35095836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of skin xenograft rejection by depleting T-cell receptor alpha beta-bearing cells without T-cell receptor gamma delta-bearing cells or natural killer cells by monoclonal antibody.
    Nishimura Y; Eto M; Maeda T; Hiromatsu K; Kobayashi N; Nomoto K; Kong YY; Nomoto K
    Immunology; 1994 Oct; 83(2):196-204. PubMed ID: 7835935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.